Skip to content

Nicotine You Can Pop Like a Mint: Are Dissolving Tablets a Safer Swap—or a New Risk?

In Simple Terms

Small flavored tablets that melt in your mouth deliver nicotine without smoke or a used pouch to throw away. They might help some adults move away from cigarettes, but they still contain an addictive drug and can look appealing to children. It is not yet clear whether they help smokers quit or simply make nicotine easier for more people to use.

A Small New Product in a Fast-Changing Market

Cigarette alternatives are no longer limited to vaping devices and small pouches tucked between the lip and gum. In Britain, flavored nicotine tablets that dissolve in the mouth are now appearing as a discreet, convenient option. But the very simplicity that makes them easy to use has drawn the attention of public-health experts, who want to know whether these products actually reduce smoking or broaden nicotine dependence.

Japan Tobacco International launched its Perlz product in the United Kingdom in May 2026, while Philip Morris International introduced Zyn Melts in Britain and Switzerland. Nic Nac tablets, made by a U.S. startup based in Spokane, Washington, have been on the American market since 2022 and are now available in about 3,000 stores.

Users place the tablets near the gum and let them dissolve, releasing nicotine. They are used much like nicotine pouches, but do not leave behind a damp pouch that must be discarded. They are sold in flavors such as mint and berry and come in colorful packaging. Those features may feel familiar to consumers, but they also raise questions about whether the tablets could be mistaken for ordinary products or candy.

Erwin Henriques, a global analyst at market research firm Euromonitor, sees the tablets as a predictable extension of the growing nicotine-pouch market. A dissolving tablet resembles familiar items such as lozenges or some supplements. That resemblance, however, does not make it harmless: the active ingredient is nicotine, which can cause dependence even when it is not inhaled in smoke.

Lower Doses Do Not Mean No Risk

Nicotine levels vary from one product to another. Zyn Melts and Perlz are available in two strengths, 1 and 2 milligrams. Nic Nac tablets come in 3- and 6-milligram strengths. Nic Nac Naturals co-founder and CEO Nico Magnotto says his company’s tablets release nicotine over about 30 minutes, so their effects last more like those of a pouch than those of a faster-dissolving tablet.

For comparison, the most common nicotine pouches contain between 3 and 17 milligrams. Philip Morris recently introduced a 1.5-milligram pouch for people just starting to try nicotine pouches. But comparing the numbers alone cannot determine a product’s risk or its effects. The dose, how quickly nicotine reaches the body, how often someone uses the product, and the user’s age all matter. A lower-dose tablet still contains nicotine and can still lead to dependence.

Companies market the tablets to adults who use nicotine, presenting them as smoke-free and easy to carry. Philip Morris describes its tablets as delivering a quicker experience than pouches, whose effects and flavor last longer. Japan Tobacco presents Perlz as a new step beyond vaping devices and pouches. These messages emphasize convenience, but they do not answer a basic question: does a smoker switch completely from cigarettes, or simply add another product to the habit?

The Real Test: Do the Tablets Replace Cigarettes?

Tobacco companies argue that noncombustible nicotine products are less harmful than cigarettes and may help adults move away from smoking. The U.S. Food and Drug Administration has allowed some related products, including nicotine pouches and heated tobacco, to be marketed on the basis that they are less harmful than cigarettes and may help some smokers quit. But permission to market a product—or a finding that it is less harmful than cigarettes—does not mean it is safe or prove that users will stop smoking.

Public-health advocates point out that some people use new products alongside cigarettes rather than switching completely. If someone continues to smoke while using tablets or pouches, they may not gain the expected benefit of avoiding cigarette smoke. Evidence that these products lead large numbers of smokers to switch entirely remains limited, even as the choices for people who want to consume nicotine in different ways continue to grow.

The effects of smoking reach far beyond individuals: tobacco-related diseases cause about 7 million deaths worldwide each year and rank among the leading preventable causes of death. Health authorities are therefore looking for ways to reduce smoking and the harm it causes, but they face a difficult balance. Alternatives may help some adults, yet they could also become an entry point for new users or make nicotine a more familiar part of everyday life.

Minty Appeal Raises Concerns About Children

Companies say they do not target underage users. Japan Tobacco says Perlz’s design and marketing are not intended to appeal to anyone below the legal age, and that its packaging has a safety mechanism requiring three buttons to be pressed at the same time to open it. Magnotto says his company does not promote Nic Nac to young people and that its research suggests teenagers see the tablets as more like medicinal products than trendy ones. He adds that the company uses tested child-resistant packaging and is preparing an even safer mechanism.

Still, company safeguards do not eliminate concerns about the tablets’ appearance, flavors, and portability. A dissolving tablet may look like candy or a familiar medicine, and its form may not reveal that it contains nicotine. Magnus Lundbäck, a cardiologist, nicotine researcher, and professor at Karolinska Institutet in Stockholm, warns that the product could appear harmless to children and teenagers even though its contents are not.

These concerns come amid earlier experiences with new nicotine products. Vaping spread so rapidly in 2018 that the U.S. Food and Drug Administration described youth use as an epidemic. Attention later shifted to nicotine pouches, and surveys have found that their use among teenagers has risen in recent years, even though the industry says the share of young people who use them remains low.

Reports from U.S. poison control centers show another side of the risk: calls related to nicotine poisoning, many involving pouches, nearly doubled between 2024 and 2025. Children under age 6 were involved in three-quarters of the cases recorded last year. These figures are not specific to the new tablets, but they are a reminder that nicotine products left within children’s reach can cause accidental poisoning—and that child-resistant packaging does not remove the need to store them safely out of reach.

A Growing Market Encourages More Nicotine Formats

Commercial figures help explain why new forms of nicotine are appearing. Global sales of nicotine pouches reached $9.2 billion in 2025, according to Euromonitor estimates. The volume of pouches sold grew at an annual rate of 50% over the previous five years, and a report Henriques prepared in July forecast continued growth of 20.5% a year.

A market expanding this quickly gives companies an incentive to develop products that are easy to use in different settings, without smoke or a visible device. Henriques says demand for stimulants is partly linked to consumers’ growing stress. But explaining the appeal does not change the fact that more options may also create more opportunities to start using nicotine or to keep using it. Convenience is not a measure of health benefit, and commercial growth does not prove that smokers are giving up cigarettes.

Brands are also moving toward presenting nicotine as part of a lifestyle rather than simply as a smoking alternative. This year, Philip Morris filed applications to protect trademarks associated with the Zyn name, including House of Zyn and Zyn Club. It also sought protection for the Zyn Melts name in the United States and Europe, both as a consumer nicotine product and as a medicinal aid to quitting. These filings do not prove the products will be sold in every one of those markets, but they show how much commercial interest is gathering around the brand and new ways to use nicotine.

Britain Becomes a Test Market Before Tighter Rules

The United Kingdom offered a suitable launch market for nicotine tablets because products containing nicotine did not require advance regulatory approval in the same way as some medicines. The tablets appeared before tougher rules under the Tobacco and Vaping Act 2026 began to take effect in October. The law included restrictions such as a ban on promotional gifts and steep discounts on tobacco and nicotine products.

In the United States, nicotine tablets used as medicines to help people quit smoking are treated differently from similar tablets sold to the public as consumer products. Medicinal tablets require specific approval from the Food and Drug Administration, while nicotine tablets intended for general use need a separate review. In 2023, Nic Nac Naturals submitted an application to market nine varieties of its mint- and fruit-flavored tablets to the U.S. public.

Mitch Zeller, the former director of the FDA’s Center for Tobacco Products, says these tablets could be a useful option for some smokers if sold in a well-regulated market, but stresses the need for a comprehensive scientific review before a decision is made. That review, he says, should examine how different groups of users respond, including the possibility that teenagers might use the products or that children might accidentally swallow them.

The issue is especially sensitive because a new FDA rule allows some nicotine products to be sold while their applications are still under review. That could put products in stores before studies of their effects and appeal to teenagers are complete. Zeller warns that both intended and unintended consequences should be assessed before marketing—not after a product has become widely available.

What Do the Tablets Need to Prove?

The new tablets combine two very different promises. For adults who smoke, they offer nicotine in a way that may be less harmful than inhaling cigarette smoke. At the same time, their small size and easy use could attract people who might never have used pouches or vaping devices. Their public-health impact cannot be judged by looking at the packaging or comparing the nicotine amount with that of another pouch. What matters is who uses them, how they use them, whether they truly replace cigarettes, and whether they increase nicotine use among new groups.

Any assessment should also consider the risks of using the products alongside cigarettes, the chance of accidental poisoning, and how well the packaging protects children. A mechanism that requires three buttons to be pressed may make a package harder for a child to open, but it does not make safe storage unnecessary. Regulators need more than a company’s description of a product as intended for adults. They need independent evidence about how it performs in the market and how its design and flavors affect people of different ages.

Lundbäck says the broader public-health goal should not be to invent more ways to consume nicotine, but to reduce the number of people who depend on it. That does not rule out the possibility that a less harmful alternative could help some smokers quit cigarettes. It does, however, put the burden of proof on companies and regulators: they must show a benefit for adult smokers while limiting children’s and teenagers’ access and preventing the products from becoming a starting point for new habits.

The Bottom Line

Perlz, Zyn Melts, and Nic Nac offer a new way to use nicotine: a small tablet that dissolves in the mouth, needs no flame or device, and leaves no used pouch to throw away. Those features may help some adults looking for an alternative to cigarettes. But a lower dose or the absence of smoke does not mean there is no risk, and marketing a product to adults cannot guarantee that children will not be curious about it or get hold of it by accident.

The boom in nicotine pouches—which reached $9.2 billion in sales in 2025—shows the scale of the market these tablets are entering. Poisoning reports and concerns about teen use make caution essential. Before these products can be considered a public-health advance, evidence must show that they help smokers switch completely away from cigarettes, their effects must be carefully studied, and rules must protect children. The key test is not how easy a tablet is to use, but whether it reduces nicotine dependence rather than making nicotine easier to consume and more widespread.